Condition Directory

Breast Cancer clinical trials

Directory of U.S. ClinicalTrials.gov public records for Breast Cancer. Browse Breast Cancer recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced November 15, 2026 Report an issue

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:11 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

7089

Shown on this page

Current sort

How Breast Cancer studies are organized in the registry

Breast cancer listings are usually subtype-specific: receptor status appears directly in titles and condition fields, so subtype terms narrow results far better than stage words alone. Many studies also restrict to either early-stage or metastatic settings, which is visible in the title or eligibility section of the official record.

Terms that often appear in related listings

triple-negative HER2-positive hormone receptor-positive metastatic breast cancer

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Showing 853–864 of 7,089 matching trials for Breast Cancer.

Live ClinicalTrials.gov results.

Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search

Conditions: Metastatic Breast Cancer, HER2-positive Breast Cancer, EGFR Overexpression, Metastatic Esophageal Carcinoma, HER-2 Positive Esophageal Cancer
Interventions: Combination of MVF-HER-2 (597-626) and MVF-HER-2 (266-296) emulsified with ISA 51; Biological
Lead sponsor: Pravin T.P Kaumaya; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Indianpolis, Indiana

Conditions: Breast Cancer, Breast Neoplasms, Breast Adenocarcinoma, Breast Cancer Stage, Breast Cancer Stage IV, Breast Cancer Invasive, Breast Cancer in Situ
Interventions: Not listed
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 22
States / cities: Los Angeles, California • San Francisco, California • Aurora, Colorado + 16 more

Conditions: Breast Cancer Survivors
Interventions: Exercise training; Behavioral
Lead sponsor: University of Florida; Other
Eligibility: 40 Years to 80 Years · Female only
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Receptors, Estrogen, Genes, Erbb-2, Breast Neoplasms
Interventions: Palbociclib (75, 100, 125 milligram [mg]), H3B-6545 (150, 300, 450 mg); Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 5
States / cities: Sarasota, Florida • Boston, Massachusetts • Kansas City, Missouri + 2 more

Conditions: Breast Carcinoma
Interventions: Non-Interventional Study; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 100 Years · Female only
Enrollment: 4,500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2030
U.S. locations: 2
States / cities: Jacksonville, Florida • Rochester, Minnesota

Conditions: Estrogen Receptor-positive Breast Cancer, Musculoskeletal Complications, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions: anastrozole; Drug
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years and older · Female only
Enrollment: 1,046 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2026
U.S. locations: 2
States / cities: Boston, Massachusetts • East Orange, New Jersey

Conditions: Breast Cancer, Breast Carcinoma
Interventions: Adaptive Aerobic Training/AT Dosing, Standard (fixed) Aerobic Training/AT dosing; Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Estrogen Receptor Positive Breast Cancer, Progesterone Receptor Positive Tumor, Recurrent Breast Carcinoma, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer
Interventions: Exemestane, Laboratory Biomarker Analysis, Oophorectomy, Quality-of-Life Assessment, Radiation Therapy, Tamoxifen, Triptorelin; Drug · Other · Procedure + 1 more
Lead sponsor: ETOP IBCSG Partners Foundation; Network
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 3,066 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2024
U.S. locations: 480
States / cities: Birmingham, Alabama • Anchorage, Alaska • Scottsdale, Arizona + 323 more

Conditions: Breast Cancer, Peripheral Neuropathy
Interventions: Desloratodine, Placebo; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Advanced ER-Positive HER2-Negative Breast Cancer
Interventions: AZD9833, Fulvestrant; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years · Female only
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 9
States / cities: Birmingham, Alabama • Long Beach, California • Fort Myers, Florida + 6 more

Conditions: Breast Cancer, HER2-low Breast Cancer, Metastatic Breast Cancer, HER2-negative Breast Cancer
Interventions: Trastuzumab Deruxtecan, Datopotamab Deruxtecan; Drug
Lead sponsor: Ana C Garrido-Castro, MD; Other
Eligibility: 18 Years and older
Enrollment: 357 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2038
U.S. locations: 11
States / cities: Birmingham, Alabama • San Francisco, California • New Haven, Connecticut + 7 more

Conditions: Breast Cancer, Patient Reported Outcomes
Interventions: Patient Reported Outcome Measure Survey result feedback; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: Female only
Enrollment: 925 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2029
U.S. locations: 3
States / cities: Denver, Colorado • Highlands Ranch, Colorado

About this Breast Cancer clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Breast Cancer as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Breast Cancer.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Breast Cancer clinical trials

How Breast Cancer studies are organized in the registry

Filter and sort this condition

Live official records

HER-2 B Cell Peptide Vaccine

Multi-Institutional Transgender & Gender-Diverse Breast Cancer Study

Rowing Following Breast Cancer Chemotherapy

A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer

Integrating Molecular Pathology, Radiology, and Genetics to Improve Breast Cancer Risk

A Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)

Study of Aerobic Training for People Receiving Treatment for Breast Cancer

Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

Desloratadine to Prevent Taxane-induced Peripheral Neuropathy in Patients With Breast Cancer

A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer

TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd

Breast Cancer Patient Engagement With Patient Reported Outcome Measure Survey

About this Breast Cancer clinical trials directory page